Medical robots are categorized into surgical robots, exoskeleton rehabilitation robots and nursing robots. In the past few days, I focused on understanding the field of surgical robots, the overall feeling is that the domestic market for medical robots is very large, and not too many good companies in China, but there are companies with independent intellectual property rights such as Tianzhihang. And some listed companies to label themselves as "robots", be cautious.
Da Vinci penetration rate of 4.3% in China
In the field of surgery, surgical medical robots have obvious advantages: less bleeding of the patient, faster recovery, and shorter training time for doctors. Surgery will move from "resection" to "repair". Therefore, in the next few years, surgical medical robots should be rapidly popularized in China.
Talking about this field, first of all, we should mention the United States Intuitive Surgical company in 1999 produced the "da Vinci", has been widely used in the prostate and other kinds of surgery. There is a video on the Internet that shows Leonardo da Vinci sewing the skin of a grape delicately, which is amazing.
Da Vinci in the U.S. hospital market penetration has reached 47%, the United States has 4,974 community hospitals, has installed 2,344 da Vinci. That's a 47 percent penetration rate.
At the end of 2014, da Vinci had 3,473 devices worldwide, with revenues of $2.13 billion and net income of $510 million for the full year of 2014, and the company's market capitalization has reached $50 billion.
In 2014, da Vinci's revenue mix consisted of $630 million in new devices sold; $1.07 billion in consumables; and $430 million in annual service fees ($100,000-$170,000 per unit per year). This revenue model has also served as a model for other medical robotics companies around the world.
In 2000, on the other hand, da Vinci's revenues were in the neighborhood of $20 million, with an $18 million loss.
The People's Liberation Army's (PLA) 301 Hospital began introducing da Vinci in 2006 and has done many surgeries. There are now six da Vinci units at 301 Hospital.
However, da Vinci costs around 20 million yuan per unit, along with the cost of supplies and services. The average hospital can't afford it. By the third quarter of 2015, there were 46 da Vinci units in China, and there were 1,079 tertiary hospitals in China, a penetration rate of 4.3%. From another perspective, this also shows that China's medical robotics industry still has much to offer.
In addition to da Vinci, other international brands of medical robots include spinal robots from Israel's Mazor Robotics; neurosurgical positioning robots from France's Medtech; articulated robots from the U.S.'s Curexo; and articulated robots from the U.S.'s Mako.
North Aerospace Zhihang leads the way at home
Overall, medical robots in China are still in their infancy, and there is a big gap between them and da Vinci. Meanwhile the localization of surgical robots has been in the beginning.
Domestic in the surgical robot better: HIT Sizhe Rui, North Aerospace Zhihang, Tianjin University Miaohan robot.
1, North Aerospace Zhihang
Tian Zhihang is mainly in the field of orthopedics, orthopedic surgery does not involve internal organs, easier modeling, suitable for robots. Tianzhihang (834360) has been listed on the New Third Board.
Surgical robots belong to the third class of medical devices. Clinical verification is required to obtain a license, and the time to obtain a license is 2-5 years. Tianzhihang's products originate from the results of the 863 project completed by Beijing University of Aeronautics and Astronautics and Beijing Jishuitan Hospital. In February 2010, TIANZHIANG obtained the registration license for orthopedic robotic products (State Food and Drug Administration Measures Quasi-Zi [2010] No. 3540188), which is China's first orthopedic robot with completely independent intellectual property rights. This is the first medical robot product with completely independent intellectual property rights in China. The company has also become the fifth company in the world to obtain the registration license for medical robots.
The robot has been applied in many medical institutions, such as Beijing Jishuitan Hospital, 301 Hospital, the Third Hospital of Hebei Medical University, the Second People's Hospital of Shenzhen, the Fourth People's Hospital of Zigong, Haidian Hospital of Beijing, Changping District Hospital of Beijing, the Central Hospital of Karamay in Xinjiang, and the People's Hospital of Hebi.
Tianzhihang reported a loss of 12.7 million yuan in 2014 on revenues of 38 million yuan.
2, Harbin Institute of Technology SZR
SZR is a research and development of minimally invasive laparoscopic surgical robots, SZR's general manager is Harbin Institute of Technology professor, Harbin Institute of Technology Robotics Research Institute, deputy director of Professor Du Zhijiang. In May of this year, BOSHI shares with 100 million yuan RMB to buy 20% of the shares of SZERY.
3, Tianjin University robot
In 2014, Tianjin University successfully developed the "My hand A robot system". The system is mainly used for minimally invasive abdominal surgery. In April last year, Xiangya Third Hospital of Central South University was the first in China to adopt the "Miaohan S" robot, which has been used to repair gastric perforation and appendectomy for three patients.
A-share "robot concept stock" water quite a lot
Domestic companies listed on the A-share market have also labeled themselves as "robots", and health care related to the main: Chutian Science and Technology (300358), BOSHI stock ( 002698) Hesco (002653). However, from the following three cases, Boshi shares of the foundation is better, and Chutian technology and Haisike just have a little robot concept only.
(1) Chutian Technology
Chutian Technology and the National Defense University cooperation exoskeleton rehabilitation robot, three years after the launch of samples.
(2) Hysco
Hysco spent $10.5 million to buy part of Israeli medical device company MST, whose robotic system, called "Autolap," is mainly used in laparoscopic surgery. Hiscox has been granted a 15-year license to sell Autolap in China.
(3)Boshi Stocks
Boshi Stocks is the industrialization base of the Robotics Research Institute of Harbin Institute of Technology (HIT), which is the strongest institute in China in terms of robotics technology. In November 2013, the minimally invasive laparoscopic surgical robotic system developed by the Robotics Research Institute of HIT passed the national "863" standard and was approved by the State Council. The "863" program was accepted by a group of experts.
Boswell shares of 100 million yuan to participate in the Harbin Institute of Technology "minimally invasive surgical robots and intelligent instruments project" (SZR) 20% stake, is expected to launch new products in 2016-2017.